Documents and PDFs
Fibrinolytic Inhibitors in the Management of Bleeding Disorders
A description of the mechanism of action of fibrinolytic inhibitors and their use in the treatment of inherited bleeding disorders
Year: 2025
Language: English
This resource is also available in:
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy.
Learn more about different treatment options for hemophilia with the World Federation of Hemophilia Shared Decision Making tool!
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
A description of the mechanism of action of fibrinolytic inhibitors and their use in the treatment of inherited bleeding disorders
This report reviews the spectrum of indications of desmopressin in the treatment of bleeding disorders.
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia
Presents data on the reported use of factor IX (FIX) per country. FIX use varies considerably, even among the wealthiest
Presents data on the reported use of factor VIII (FVIII) per country. FVIII use varies considerably, even among the wealthiest
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia